IL-6/STAT3 is closely related to tumor cells drug resistance, and the upregulation of the tumor inflammatory factor IL-6 can promote mitogen activation of protein kinase (MAPK) through the activation of signaling pathways, such as the IL-6/STAT3, PI3K/Akt, and Ras-MAPK pathways, thus upregulating the expression of various drug-resistant proteins, such as MRP, P-gp and BCRP, and leading to HCC cells resisting drug therapy (95). This evidence concerns the gene IL6 and neoplasm.